- Policy
- "Chickenpox vaccine 'Sky Varicella Inj' is safe…"
- by Lee, Jeong-Hwan Jun 13, 2024 05:48am
- The Korea Disease Control and Prevention Agency (KDCA) reported on June 12th that experts and related agencies have conducted an investigation and analysis in response to an increased number of adverse reactions reported following vaccination with 'Sky Varicella Inj,' a varicella virus vaccine, and they confirmed that there are no safety c
- Policy
- CPAC ‘Scemblix’s orphan drug designation is valid’
- by Lee, Hye-Kyung Jun 13, 2024 05:48am
- The next-generation chronic myeloid leukemia drug ‘Scemblix (asciminib)’ is expected to be available for adult patients with chronic myeloid leukemia (CML) with the T315I mutation or Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ ALL) with the T315I mutation. According to the minutes of the Central Pharmaceutical Affai
- Company
- A growing trend of SC injections heats up competition
- by Son, Hyung-Min Jun 13, 2024 05:48am
- Pharmaceutical and biotech companies in Korea and worldwide focus on developing formulation modifications for anticancer agents. Following 'Tecentriq (atezolizumab)' SC (subcutaneous injection obtaining marketing authorization from the European Medicines Agency (EMA) in January, the R&D of 'Opdivo (nivolumab)' and 'Rybrevant (amivantamab)' is
- Policy
- 9th meeting held for external reference pricing reevals
- by Lee, Tak-Sun Jun 13, 2024 05:48am
- The government and the pharmaceutical industry held the 9th meeting on external reference pricing reevaluations but reportedly decided to continue discussions. Initially, the 9th meeting was supposed to be the last in the opinion-gathering process, but further meetings were deemed inevitable.&160; According to industry sources, the
- Company
- ‘Verify safety when using botulinum toxin for hair loss'
- by Nho, Byung Chul Jun 12, 2024 05:45am
- The market for hair loss treatment is growing day by day as hair loss, once considered a typical condition of middle-aged men, has become a general condition across all genders and ages. In particular, the market is being segmented across a wide age range and various lifestyles, and new treatments that complement the limitations of existin
- Company
- Autotelic Bio signs licensing agreement with Chinoin
- by Nho, Byung Chul Jun 12, 2024 05:45am
- Autotelic Bio announced on the 7th that it has signed an exclusive license and supply agreement with Chinoin Productos Farmaceuticos in Mexico to distribute ATB-101, a novel combination drug for the treatment of hypertension and diabetes. ATB-101 is a fixed-dose combination product comprising&160;of the hypertension drug ‘olmesartan’
- Company
- Failed reimb negotiations for Lorviqua, was it for the best?
- by Eo, Yun-Ho Jun 12, 2024 05:45am
- After a long wait, the result was still a ‘no go.’ A solution does exist, but hesitation seems to be holding them back. The insurance reimbursement expansion for the 3rd-generation ALK anticancer drug Lorviqua to first-line therapy has become unclear again. Negotiations between Pfizer Korea and the National Health Insurance Service o
- Policy
- Price ceiling for 'atosiban' set to rise under agreements
- by Lee, Tak-Sun Jun 12, 2024 05:45am
- The insurance drug price ceiling for atosiban injection, used to delay pre-term birth in pregnant adult women, will increase. Currently, three products of atosiban for injection are available. With the drug price ceiling adjustment, better supply is expected following negotiations related to expanding the volume of distribution. Acc
- Company
- Boryung wins the Pomalyst patent challenge for the 2nd time
- by Kim, Jin-Gu Jun 11, 2024 03:25pm
- Boryung won the second attempt to avoid the substance patent of ‘Pomalyst (pomalidomide),‘ a treatment for multiple myeloma. Despite winning the infringement trial for the same patent in 2021, Boryung had not released generic versions. It seems that Boryung changed the method of generic development and rechallenged the patent. The an
- Product
- Selection dilemma rises in IBD mkt due to increased options
- by Moon, sung-ho Jun 11, 2024 05:48am
- With the recent surge in treatment options for inflammatory bowel disease (IBD), which is represented by ulcerative colitis and Crohn's disease, developing an appropriate treatment strategy for IBD is emerging as a rising topic in clinical practice. This is due to the recent health insurance reimbursement extensions granted for treatments by
